Front. Neurol. Frontiers in Neurology Front. Neurol. 1664-2295 Frontiers Media S.A. 10.3389/fneur.2024.1351925 Neurology Systematic Review Elevated troponin levels as a predictor of mortality in patients with acute stroke: a systematic review and meta-analysis Gulia Annu Srivastava Manyata Kumar Pradeep* Clinical Research Unit, All India Institute of Medical Sciences, New Delhi, India

Edited by: Faraz Rashid, Henry Ford Health System, United States

Reviewed by: Brandon Peter Lucke-Wold, University of Florida, United States

Robert Daniel Nass, University Hospital Bonn, Germany

 *Correspondence: Pradeep Kumar, pradeepguptaneuro@gmail.com; pradeepgupta@aiims.edu 25 03 2024 2024 15 1351925 07 12 2023 29 02 2024 Copyright © 2024 Gulia, Srivastava and Kumar. 2024 Gulia, Srivastava and Kumar

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

 Background and Aim

The prognostic potential of cardiac troponin (cTn) in acute stroke patients has been a subject of ongoing debate. Our objective was to provide a comprehensive evidence for predicting mortality in acute stroke patients by using the elevated troponin levels.

 Methods

We conducted an extensive literature search, including PubMed, EMbase, and Trip Databases, covering studies published up to September 30, 2023. We computed risk ratios (RR) with 95% confidence intervals (CIs), performed sensitivity analysis, and conducted trial sequential analysis (TSA).

 Results

In total, 53 studies were analyzed, with 37 focusing on acute ischemic stroke (AIS), 11 on subarachnoid hemorrhage (SAH), and 7 on Intracerebral hemorrhage (ICH). Elevated cTn levels were significantly showed a higher predictive risk for In-hospital mortality in both AIS (RR=3.80, 95% CI; 2.82 to 5.12) as well as SAH (RR=2.23, 95% CI; 1.64 to 3.02). However, no significant predictive risk between elevated cTn levels and in-hospital mortality for ICH patients (RR=1.13, 95% CI: 0.46 to 2.79). A similar pattern was observed for elevated cTn levels, indicating an increased risk of last follow-up mortality for AIS (RR=2.41, 95% CI: 1.98 to 2.93) and SAH (RR=3.08, 95% CI: 2.25 to 4.21).

 Conclusion

Elevated troponin levels can serve as a promising predictive marker for both in-hospital and last follow-up mortality in AIS and SAH patients but not in ICH patients. Further prospective studies are needed to validate our findings along with exploring the preventive management of mortality in acute stroke settings.

 troponin mortality acute stroke ischemic stroke intracerebral hemorrhage subarachnoid hemorrhage section-at-acceptance Neurological Biomarkers Introduction

Acute stroke represents a critical medical condition with substantial implications for patient outcomes and healthcare systems (1). In this context, the timely and accurate identification of prognostic markers capable of predicting stroke-associated mortality emerges as a paramount imperative (2). Such markers not only facilitate risk assessment but also guide precise and targeted clinical interventions, ultimately influencing patient outcomes and optimizing healthcare resource allocation (3). Cardiac Troponin (cTn), widely recognized as a cardinal biomarker in cardiology, has recently attracted attention for its potential role as an indicator of mortality risk in patients afflicted by acute stroke (4).

In the short term, the immediate post-stroke period, in-hospital mortality rates for acute stroke patients can exhibit alarming elevations, with figures occasionally reaching a staggering 50% (5). The major driving force behind such acute fatalities often lies in cardiac-related complications. These complications manifest through the release of cardiac troponin-T (cTnT), cardiac troponin-I (cTnI), High-sensitive cardiac Troponin I (hs-cTnI) and High-sensitive cardiac Troponin T (hs-cTnT) proteins into the circulatory system. Importantly, during the acute phase of ischemic stroke (IS), a marked elevation in serum levels of cTnT or cTnI is frequently observed, establishing a robust link between cardiac injury and the stroke itself (6). The precise and timely prognosis of this cardiac involvement not only impacts therapeutic strategies but also plays a pivotal role in the monitoring and management of patient outcomes, fundamentally shaping the quality of healthcare delivery (7).

However, despite the potential of cardiac troponin as a prognostic marker, the scientific literature presents contrasting findings regarding its association with the risk of all-cause mortality in patients afflicted with acute stroke (8). Moreover, the precision of risk estimates demonstrates considerable variability across individual research studies. Troponin elevations have been reported in a substantial proportion of stroke patients, with prevalence rates ranging from 27% to 34% (9). These elevations have been consistently linked to heightened mortality in various stroke subtypes, encompassing IS, Intracerebral hemorrhage (ICH), and subarachnoid hemorrhage (SAH). Nevertheless, previous meta-analyses (6, 10–17) have failed to definitively establish troponin elevation as an independent and unequivocal prognostic factor in the context of acute stroke patients. As a result, the debate concerning the predictive utility of elevated cardiac troponin levels in the stroke population continues to be a subject of scientific scrutiny. Therefore, we aimed to conduct a systematic review and meta-analysis, aptly named “Elevated Troponin Levels as a Mortality Predictor in Acute Stroke,” in order to explore the utility of cTn in predicting mortality following acute stroke.

 Methods Search strategy

The Cochrane Handbook (version 5.1.0) was used to conduct a systematic review and meta-analysis (18). The preferred reporting items for systematic reviews and meta-analyses (PRISMA) were followed throughout the systematic review’s creation (19). Electronic searches were conducted in databases including PubMed, EMbase, and Trip Databases up to 30th September 2023. Additionally, the reference list of retrieved studies and previous meta-analyses, was manually search for collecting more relevant studies often missed while performing the electronic search. The search aimed to identify studies the prediction of cTn level with the mortality rate in patient with acute stroke. The search utilized a set of specific keywords, including (“Troponin” OR “Cardiac Troponin” OR “cTnT” OR “cTnI” OR “Troponin I” OR “Troponin T” OR “High Sensitive Troponin” OR “High Sensitive Troponin I” OR “hTnI” OR “High Sensitive Troponin T” OR “hTnT”) AND (“Stroke” OR “Brain Stroke” OR “Acute Stroke” OR “Ischemic Stroke” OR “Cerebral Infarction” OR “Intracerebral Hemorrhage” OR “Hemorrhagic Stroke” OR “Subarachnoid Hemorrhage” OR “Aneurysmal Subarachnoid Hemorrhage”) AND (“Mortality” OR “Mortality Rate” OR “Death” OR “Death Rate” OR “Prognosis” OR “Outcome”).

 Selection criteria

Inclusion Criteria:

Published observational studies, including prospective cohort and retrospective cohort studies that investigate the predictive utility of Cardiac Troponin (cTn) as a biomarker for mortality in patients with acute stroke.

Studies that report data related to either in-hospital mortality and/or last follow-up mortality as endpoints.

Studies that provide data on cTn assay results at least for a single time point during the course of the study.

Studies involving human participants.

Exclusion Criteria:

Case reports, case series, review articles, gray literature, and editorials.

Studies not reporting relevant outcomes.

Unavailability of full-texts.

Data extraction

Two independent authors (“A” and “MS”) conducted a meticulous evaluation of the identified articles to assess their eligibility for inclusion in our study. Upon the initial screening, the authors proceeded to a comprehensive examination of the full-text articles to validate their eligibility and to systematically extract relevant data. To facilitate this process, a standardized data extraction form was utilized, ensuring uniformity and thoroughness in data collection process. The following data was extracted from studies: First Author’s Name, Published year, Country, Study design, Study period, Sample size of elevated cTn and normal cTn groups, source, cTn cut-off value, cTn assessment time point, cTn type, cTn estimation method, In-hospital mortality, Last follow-up mortality outcome measured. The values of cTn levels were reported with different units in the included studies and were converted to similar units for analysis purpose using online unit conversion tools.1, 2 Any disagreement were resolved through discussion with the corresponding author.

 Quality assessment

The quality of the included studies was assessed using the Newcastle-Ottawa Scale (NOS) for observational cohort studies (20). The NOS evaluates study quality across three domains: selection of participants, comparability of groups, and ascertainment of outcomes. Studies were assigned scores ranging from 0 to 9, with higher scores indicating higher quality. Any discrepancies in quality scores were resolved through consensus with the corresponding author.

 Publication bias

To assess publication bias, we employed a funnel plot analysis (21). Egger’s regression test was used to ascertain the asymmetry of funnel plots (22).

 Statistical analysis

A fixed/random-effects model was used to calculate the pooled risk ratio (RR) with 95% confidence interval (CI). Heterogeneity was calculated with the I2 statistic. The heterogeneity was considered as significant in case of I2 more than 50% for which random effects model was applied, on the other hand, if I2 was less than 50%, then fixed-effect model was applied. Sensitivity analysis was performed by sequentially omitting a single study in each turn, to validate the pooled observed effect. In order to ascertain the sufficiency of our sample size and the statistical power of our meta-analysis, we conducted Trial Sequential Analysis (TSA). Tests were considered statistically significant at a p-value less than 0.05. All statistical analyses were carried out using STATA, version 12.0 (Stata Statistical Software, Release 12; StataCorp LP, College Station, TX).

 Results Search results and study characteristics

Figure 1 illustrates the PRISMA flow diagram detailing the inclusion and exclusion criteria for studies in our systematic review and meta-analysis. Initially, 1,234 studies were identified across three databases and from other sources. After removing duplicates, 237 articles remained, and following further exclusions, 62 full-text articles were assessed for eligibility. Finally, 53 studies (23–73) were included that examined the role of elevated troponin for predicting mortality in acute stroke. Among these studies, 37 studies focused on AIS patients (23–59), 11 on SAH patients (28, 53, 60–68), and 7 on ICH patients (28, 53, 69–73). The AIS studies involved 3,606 patients with elevated troponin and 14,099 patients with normal troponin, the SAH studies involved 450 patients with elevated troponin and 980 patients with normal troponin, and the ICH studies involved 1,041 patients with elevated troponin and 1,259 patients with normal troponin. Geographically, 24 AIS studies were conducted in Caucasian regions (23–38, 41, 42, 44, 49, 50, 53, 55, 56), and 13 in Asian regions (39, 40, 43, 45–48, 51, 52, 54, 57–59). For SAH, 10 studies were in Caucasian regions (28, 53, 60–66, 68), with only 1 in an Asian region (67). In ICH, 4 studies were in Caucasian regions (28, 53, 69, 72), and 3 in Asian regions (70, 71, 73). Two studies (28, 53) were common for AIS, SAH, and ICH subjects. The publication years ranged from 2000 to 2023, and the sample sizes varied from 43 to 1,718, with detailed baseline characteristics provided in Table 1.

PRISMA flow diagram for the selection of studies and specific reasons for exclusion from the present meta-analysis.

Baseline characteristics for the included studies investigating for elevated Troponin level in predicting mortality for acute stroke patients.

S. no. References Country Study design Study period ETP(n) NTP (n) Cutoff value cTn assessment timepoint Type of cTn Estimation method Source Last follow-up duration Outcome measured
Acute ischemic stroke
1. James et al. (23) New Zealand PCS July 1997–March 1998 30 151 >0.1 ug/l Within 72 h of symptom cTnT ELISA Serum NR Troponin, mortality
2. Trooyen et al. (24) Norway PCS January 1999–June 1999 40 109 >0.4 μg/L Within 48 h of symptom cTnI MEIA Serum NR Neurological outcomes, mortality
3. Angelontanio et al. (25) Italy PCS February 2001–January 2002 18 277 >0.01 ng/mL Within 24 h of symptom cTnI RIA NR NR Mortality, non-fatal MI event, non-fatal cardiopulmonary event
4. Barber et al. (26) UK PCS NR 45 177 >0.2 μg/L Within 24 h of symptom cTnI CIA Serum 30 days Death or dependency (Rankin > 2)
5. Jensen et al. (27) Denmark PCS August 2003–October 2004 25 219 >0.03 μg/L Within 7 days after symptom hs-cTnT ELISA NR 19 months All-cause in-hospital mortality
6. Sandhu et al. (28) USA PCS NR 23 138 >0.4 ng/mL Within 24 h of symptom cTnI NR Serum NR In-hospital mortality
7. Hajdinjak et al. (29) Slovenia PCS June 2006–May 2010 16 90 >0.04 μg/L Within 24 h of symptom cTnT ELISA NR NR In-hospital mortality
8. Scheitz et al. (30) Germany RCS October 2009–October 2010 103 612 >0.03 μg/L Within 7 days after symptom cTnI ELISA NR NR Unfavorable outcome, Major neurologic improvement, In-hospital mortality
9. Jensen et al. (31) USA PCS August 2003–October 2004 65 128 >14 ng/L Within 24 h of symptom hs-cTnT CIA NR 4.4 years All-cause mortality
10. Boire et al. (32) Canada PCS October 2006–November 2010 46 362 >0.03 ug/L Within 72 h of symptom cTnI NR NR 90 days Death, myocardial Infarction, mRS score, recurrent stroke
11. Stahrenberg et al. (33) Germany PCS March 2009–February 2010 98 99 ≥6.15 pg./mL Within 24 h of symptom hs-cTnT ELISA Plasma 12 months Vascular events, all-cause mortality
12. Scheitz et al. (34) Germany PCS February 2011–Feb ruary2013 308 409 >14 ng/L Within 48 h of symptom cTnT ELISA NR NR Unfavorable neurological outcome and in-hospital mortality
13. Lasek-Bal et al. (35) Poland PCS 2013–2014 104 964 > 0.014 ng/mL Within 72 h of symptom cTnI ELISA Serum 30 days Mortality, mRS 4–6
14. Faiz et al. (36) Norway RCS June 2009–May 2010 156 131 >14 ng/L within 24 h of symptom hs-cTnT ELISA Serum NR In-hospital mortality
15. Raza et al. (37) USA RCS 2008–2010 17 183 >0.40 ng/mL Within 24 h of symptom cTnI CIA Serum 2 years Long term cardiac adverse event, all cause death
16. Batal et al. (38) USA PCS December 2008–November 2010 309 1,409 >0.1 μg/L Within 24 h of symptom cTnI CIA Serum 3 years Mortality
17. Maoz et al. (39) Israel RCS 1 year 35 177 >0.03 μg/L NR hs-cTnT NR Serum NR NIHSS and mortality
18. Su et al. (40) Taiwan RCS August 2010–March 2015 146 725 >0.01 μg/L Within 48 h of symptom cTnI ELISA Serum NR poor outcome and in-hospital mortality
19. Budincevic et al. (41) Croatia RCS 2007–2010 10 188 >0.5 ug/L Within 24 h of symptom cTnI NR NR NR Unfavorable outcome, death
20. Peddada et al. (42) USA RCS May 2008–December 2012 199 946 >0.120 ng/mL Within 7 days after symptom cTnI CIA Serum NR NIHSS and mortality
21. Akpinar et al. (43) Turkey RCS NR 11 53 >0.014 ng/mL Within 48 h of symptom cTnT CIA Serum Mean: 9.6 days In-hospital mortality
22. Wrigley et al. (44) USA RCS 2010 295 1,082 between 40 and 50 ng/L Within 24 h of symptom cTnT and cTnI NR Serum 3 Year Long-term mortality, Structural cardiac disease
23. Ahn et al. (45) Korea RCS May 2007–December 2014 166 1,526 >0.04 ng/mL Within 48 h of symptom cTnI CMIA Serum 33 months Long-term mortality
24. Fathy et al. (46) Egypt PCS March 2016–December 2016 14 60 >0.01 μg/L. Within 48 h cTnI ELISA Serum NR Poor short-term outcome and in-hospital mortality
25. He L. et al. (47) China RCS May 2012–December 2017 118 398 ≥14 ng/L Within 72 h hs-cTnT CIA Serum 3 months Death, Major disability
26. Ahn et al. (48) Korea PCS 2013–2015 145 947 ≥0.040 ng/mL Within 48 h cTnI CIA Serum 18 months Adverse long-term outcomes, mortality
27. He M. et al. (49) USA RCS January 2013–December 2016 25 58 0.6 ng/mL Within 48 h cTn NR NR 1 year All-cause mortality, AMI, AIS, and all-cause re-hospitalization
28. Terceno et al. (50) Spain PCS NR 42 68 ≥14 ng/L Within 24 h of symptom hs-cTnT NR Plasma 3 months Mortality, mRS, NIHSS
29. Sui et al. (51) China PCS January 2017–February 2018 65 176 >14 ng/L Within 24 h of symptom hs-cTnT NR Serum 90 days Mortality, disability
30. Cao et al. (52) China RCS January 2015–November 2017 85 58 >14 ng/L Within 48 h of symptom hs-cTnT CIA Serum 3 months Poor outcome and mortality
31. Alkhachroum et al. (53) USA RCS January 2013–April 2015 197 621 >0.04 ng/mL Within 48 h of symptom cTnI NR Serum NR Disease severity, mortality, functional outcome and discharge disposition
32. Thapa et al. (54) Nepal PCS NR 8 93 > 0.034 ng/mL Within 48 h of symptom hs-cTnI CIA Serum NR Poor outcomes and in-hospital mortality
33. Scheitz et al. (55) Germany PCS January 2010–June 2013 220 342 >14 ng/L Within 7 days of symptom hs-cTnT CIA Serum 3 year Recurrent stroke, myocardial infarction, and all-cause death
34. Nageeb et al. (56) Egypt PCS January 2017–January 2019 13 59 ≥0.01 μg/L Within 24 h after onset cTnI ELISA Serum 3 months Death, disability, neurological improvement
35. Miraj et al. (57) Bangladesh PCS NR 8 92 >0.04 ng/mL Within 7 days after symptom cTnI NR Serum NR Poor outcome and in-hospital mortality
36. Chen et al. (58) China PCS February 2016–November 2020 90 264 >0.03ug/L within 24 h after onset hs-cTnI CIA NR 90 days hscTnI, mortality
37. Kim et al. (59) Korea RCS August 2014–July 2017 311 708 20.7 ng/L for men and 16.1 ng/L for women within 24 h of symptom hs-cTnI CIA NR 22.5 months Mortality and cardiac and cerebrovascular events
Subarachnoid hemorrhage
38. Deibert et al. (60) USA PCS January 1998–August 2000 12 31 ≥1.4 ug/L On admission cTnI NR Serum NR Home, acute rehabilitation, nursing home and death
39. Naidech et al. (61) USA PCS November 1998–October 2002 46 81 >0 to 0.5 ug/L On admission cTnI NR Serum 3 months Functional disability or death
40. Sandhu et al. (28) USA PCS NR 20 76 >0.4 ng/mL On admission cTnI NR Serum NR In-hospital mortality
41. Ramappa et al. (62) USA PCS January 1999–December 2003 31 52 ≥2.0 ng/mL On admission cTnI NR Serum NR Worse neurological outcome and in-hospital mortality
42. Gupte et al. (63) USA RCS August 2006–June 2009 47 157 >0.5 ng/mL On admission cTnI NR NR NR In-hospital mortality
43. Duello et al. (64) USA RCS March 2011–July 2013 36 139 >0.10 ng/mL On admission cTnT NR NR 1 month Mortality
44. Guette et al. (65) France PCS October 2012–August 2015 76 61 >22 ng/L within 72 h of symptom onset hs-cTnT ELISA Plasma 3 months Sensitivity and specificity with corresponding 95% CIs.
45. Alkhachroum et al. (53) USA RCS January 2013–April 2015 48 75 >0.04 ng/mL On admission cTnI NR Serum NR Disease severity, Mortality, functional outcome and discharge disposition
46. Akkermans et al. (66) Netherland PCS November 2005–February 2008 43 116 >12 ng/L NR cTnI NR Serum 1 year Myocardial infarction, cardiac death, all-cause mortality
47. Lin et al. (67) China PCS January 2016–December 2017 55 158 >0.016 ng/mL On admission cTnI NR NR 34.3 months Major adverse cardiac events, long-term neurological outcomes, and mortality
48. Anetsberger et al. (68) Germany PCS March 2013–December 2015 36 34 >0.007 μg/L On admission cTnT ELISA NR 3 months Functional outcome and mortality
Intracerebral hemorrhage
49. Hays et al. (69) USA RCS January 2001–January 2005 38 84 >0.10 ng/mL within 24 h cTnI RIA Serum NR In-hospital mortality
50. Sandhu et al. (28) USA PCS NR 14 80 >0.4 ng/mL within 24 h cTnI NR Serum NR In-hospital mortality
51. Chung et al. (70) South Korea RCS January 2003–December 2007 28 225 >0.01 ng/mL Within 24 admission hours cTnT ELISA Serum NR In-hospital mortality
52. Xu et al. (71) China RCS NR 66 122 NR NR cTnI NR NR NR In-hospital mortality, GCS < 8, NIHSS >10
53. Gerner et al. (72) Germany PCS 2006–2014 83 437 >0.040 ng/mL Within 72 h after admission cTnI CIA Plasma NR Functional outcome
54. He et al. (73) China RCS June 2012–December 2015 729 88 ≥0.028 ng/mL NR cTnI CIA Serum NR In-hospital mortality and mRS
55. Alkhachroum et al. (53) USA RCS January 2013–April 2015 83 223 >0.04 ng/mL On admission cTnI NR Serum NR Disease severity, mortality, functional outcome and discharge disposition

RCS, Retrospective Cohort Study; PCS, Prospective Cohort Study; cTnI, Cardiac troponin I; cTnT, Cardiac troponin T; hs-cTnT, High-sensitive cardiac Troponin T; hs-cTnI, High-sensitive cardiac Troponin I; NIHSS, National Institute of Health Stroke Scale; GCS, Glasgow Coma Scale; mRS, Modified Rankin Scale; NR, not reported; ELISA, enzyme-linked immunosorbent assay; CIA, chemiluminescence immunoassay; RIA, radioimmunoassay; MEIA, Microparticle Enzyme Immunoassay; CMIA, chemiluminescent microparticle immunoassay.

Regarding predictive mortality outcomes, 15 studies with AIS patients (23–25, 28–30, 34, 36, 39–43, 54, 57), 6 with SAH (28, 53, 60, 62, 63, 67), and 7 with ICH (28, 53, 69–73) reported data for In-hospital mortality. For last follow-up mortality, 22 AIS studies (26, 27, 31–35, 37, 38, 44–53, 56, 58, 59) and 6 SAH studies (61, 64–68) provided relevant data. Only a single study (67) reported data both In-hospital mortality and last follow-up mortality for SAH subjects. The majority of studies included in our review received high ratings on the NOS Scale, indicating strong methodological quality (Table 2). Each study’s total score, ranging from 6 to 9, reflects its overall quality, supporting the reliability and validity of the evidence presented in this review.

Quality assessment of included studies based on Newcastle-Ottawa Scale (NOS).

Selection Comparability Outcome Result
S. no. References Representative of the exposed cohort Selection of the non-exposed cohort Ascertainment of exposure Demonstration that outcome was not present at study start Comparability of cohorts based on design or analysis Assessment of outcome Enough follow up period Adequacy of follow up Total score
Acute ischemic stroke
1. James et al. (23) 1 1 1 1 1 1 1 7
2. Trooyen et al. (24) 1 1 1 1 1 1 6
3. Angelontanio et al. (25) 1 1 1 1 2 1 1 1 9
4. Barber et al. (26) 1 1 1 1 2 1 1 1 9
5. Jensen et al. (27) 1 1 1 1 2 1 1 1 9
6. Sandhu et al. (28) 1 1 1 1 1 1 6
7. Hajdinjak et al. (29) 1 1 1 1 2 1 7
8. Scheitz et al. (30) 1 1 1 1 2 1 7
9. Jensen et al. (31) 1 1 1 1 2 1 1 8
10. Boire et al. (32) 1 1 1 1 2 1 1 1 9
11. Stahrenberg et al. (33) 1 1 1 1 2 1 1 1 9
12. Scheitz et al. (34) 1 1 1 1 2 1 7
13. Lasek-Bal et al. (35) 1 1 1 1 1 1 6
14. Faiz et al. (36) 1 1 1 1 2 1 7
15. Raza et al. (37) 1 1 1 1 2 1 1 1 9
16. Batal et al. (38) 1 1 1 1 2 1 1 8
17. Maoz et al. (39) 1 1 1 1 2 1 7
18. Su et al. (40) 1 1 1 1 2 1 7
19. Budincevic et al. (41) 1 1 1 1 1 1 6
20. Peddada et al. (42) 1 1 1 1 2 1 7
21. Akpinar et al. (43) 1 1 1 1 1 1 1 7
22. Wrigley et al. (44) 1 1 1 1 2 1 7
23. Ahn et al. (45) 1 1 1 1 2 1 1 1 9
24. Fathy et al. (46) 1 1 1 1 2 1 7
25. He L. et al. (47) 1 1 1 1 2 1 1 8
26. Ahn et al. (48) 1 1 1 2 1 1 7
27. He M. et al. (49) 1 1 1 1 2 1 1 1 9
28. Terceno et al. (50) 1 1 1 1 2 1 1 1 9
29. Sui et al. (51) 1 1 1 1 2 1 1 1 9
30. Cao et al. (52) 1 1 1 1 2 1 1 1 9
31. Alkhachroum et al. (53) 1 1 1 1 2 1 7
32. Thapa et al. (54) 1 1 1 1 2 1 7
33. Scheitz et al. (55) 1 1 1 1 2 1 1 1 9
34. Nageeb et al. (56) 1 1 1 1 2 1 1 1 9
35. Miraj et al. (57) 1 1 1 1 1 1 6
36. Chen et al. (58) 1 1 1 1 2 1 1 1 9
37. Kim et al. (59) 1 1 1 1 2 1 1 1 9
Subarachnoid hemorrhage
38. Deibert et al. (60) 1 1 1 1 1 1 1 1 8
39. Naidech et al. (61) 1 1 1 1 1 1 1 7
40. Sandhu et al. (28) 1 1 1 1 1 1 6
41. Ramappa et al. (62) 1 1 1 1 2 1 1 1 8
42. Gupte et al. (63) 1 1 1 1 2 1 7
43. Duello et al. (64) 1 1 1 1 2 1 1 1 9
44. Guette et al. (65) 1 1 1 1 2 1 1 1 9
45. Alkhachroum et al. (53) 1 1 1 1 2 1 7
46. Akkermans et al. (66) 1 1 1 1 1 1 1 1 8
47. Lin et al. (67) 1 1 1 1 2 1 1 1 9
48. Anetsberger et al. (68) 1 1 1 1 2 1 1 1 9
Intracerebral hemorrhage
49. Hays et al. (69) 1 1 1 1 2 1 7
50. Sandhu et al. (28) 1 1 1 1 1 1 6
51. Chung et al. (70) 1 1 1 1 2 1 7
52. Xu et al. (71) 1 1 1 1 2 1 1 1 9
53. Gerner et al. (72) 1 1 1 1 2 1 1 1 9
54. He et al. (73) 1 1 1 1 2 1 7
55. Alkhachroum et al. (53) 1 1 1 1 2 1 7
In-hospital mortality

Elevated cTn levels were significantly showed a higher predictive risk for In-hospital mortality in both AIS (RR = 3.80, 95% CI; 2.82 to 5.12; Figure 2A) as well as SAH (RR = 2.23, 95% CI; 1.64 to 3.02; Figure 2B). However, no significant predictive risk between elevated cTn levels and in-hospital mortality for ICH patients (RR = 1.13, 95% CI: 0.46 to 2.79; Figure 2C).

(A–C) Forest plot for the prediction of In-hospital mortality in (A) AIS, (B) SAH, and (C) ICH with respect to elevated cTn Levels.

Further subgroup analysis based on type of cTn, study design, Troponin cut-off value, and estimation method of troponin showed diverse patterns. Specifically for AIS subgroup analysis based on type of troponin, cTnI had a higher prediction risk (RR: 3.93; 95% CI: 2.34 to 6.60) than cTnT (RR: 3.63; 95% CI: 2.24 to 5.88) and hs-cTnT (RR: 3.34; 95% CI: 1.32 to 8.47) while hscTnI had (RR: 6.40; 95% CI: 1.21 to 33.88; Supplementary Table S1A). Based on study design, prospective cohort studies (PCS) had a higher risk (RR: 4.00; 95% CI: 2.43 to 6.57) compared to retrospective cohort studies (RCS) [RR: 3.66; 95% CI: 2.45 to 5.47]. Troponin cut-off values also showed variation, with 0.01 to 0.05 μg/L at RR: 4.55 (95% CI: 3.29 to 6.29) and 0.1 to 0.5 μg/L at RR: 2.86 (95% CI: 1.70 to 4.83). Assessment time-points within 24, 48, and 72 h had different risks.

The choice of troponin estimation methods significantly influenced risk, with Enzyme-Linked Immunosorbent Assay (ELISA) resulting in RR: 3.56 (95% CI: 2.07 to 6.12), Radioimmunoassay (RIA) at RR: 4.57 (95% CI: 2.23 to 9.34), and chemiluminescence immunoassay (CIA) at RR: 2.92 (95% CI: 2.16 to 3.96). Prediction risks varied at assessment time-points within 24, 48, and 72 h, but stability was observed for studies examining troponin levels within 24 h after Acute Ischemic Stroke (AIS). For SAH patients, subgroup analysis for showed that cTnI had a higher predictive risk for In-hospital mortality (RR = 2.23; 95% CI: 1.64 to 3.02). Both PCS (RR = 2.31; 95% CI: 1.49 to 3.58) and RCS (RR = 2.15; 95% CI: 1.40 to 3.31) also showed higher predictive role of elevated troponin for the In-hospital mortality in SAH patients (Supplementary Table S1B). For ICH, subgroup analysis revealed non-significant predictive risk between elevated cTn levels and in-hospital mortality for ICH patients (Supplementary Table S1C). Only significant association for the assessment time point of troponin levels within 24 h and within 48 h after ICH (RR = 1.76; 95% CI: 1.01 to 3.06) and (RR = 3.05; 95% CI: 1.17 to 7.91) respectively were observed (Supplementary Table S1C).

 Last follow-up mortality

Elevated cTn levels were also significantly showed a higher predictive risk for last follow-up mortality in both AIS (RR = 2.41, 95% CI: 1.98 to 2.93; Figure 3A) and SAH (RR = 3.08, 95% CI: 2.25 to 4.21; Figure 3B). Subgroup analysis showed hs-cTnT stood out with a significantly higher prediction risk (RR: 6.02; 95% CI: 2.60 to 13.93) in AIS, compared to cTnT and cTnI (Supplementary Table S2A). Both prospective and retrospective study designs, indicated an elevated predictive role of elevated troponin for last follow-up mortality in AIS and SAH subgroup analysis (Supplementary Tables S2A,B). Predictive risk remained stable for studies examining troponin levels within 24 h after AIS and SAH. Troponin estimation methods varied for AIS studies, with most utilizing CIA method, while for SAH, the predominant method was ELISA. Analysis on last follow-up mortality in ICH group was not feasible as only a single study provided data for it.

(A,B) Forest plot for the prediction of last follow-up mortality in (A) AIS and (B) SAH with respect to elevated cTn Levels.

 Publication bias

Funnel plot analysis did not reveal any apparent signs of asymmetry. The distribution of studies around the estimated effect appeared to be even, suggesting the absence of significant publication bias that could impact the results. Funnel plots for the in-hospital mortality in patients with AIS (p = 0.45), SAH (p = 0.10), and ICH (p = 0.19), and last follow-up mortality for AIS (p = 0.13), and SAH (p = 0.42), are represented in Supplementary Figures S1A–C, S2A,B.

 Sensitivity analysis

Sensitivity analysis indicated that the pooled risk estimates for in-hospital mortality in patients with AIS, SAH, and ICH was not significantly affected by the removal of any individual study (Supplementary Figures S3A–C). Similarly, the pooled risk estimates for last follow-up mortality in patients with AIS and SAH was not significantly affected by the removal of any individual study (Supplementary Figures S4A,B). Our findings suggest that the results of the meta-analysis are robust and are not driven by any single study which provides additional confidence in the validity of the findings.

 Trial sequential analysis

Our Trial sequential analysis (TSA) showed a very promising strength with 77% power with total sample size of 4,939 AIS patients and 55% power for the studies with 3,062 HS subjects. TSA plot are represented in Figures 4A,B. The high power of the TSA suggests that the meta-analysis is unlikely to be influenced by chance or random fluctuations in the data. Overall, the TSA results provide strong evidence that the meta-analysis is well-powered and that the findings are reliable and generalizable. This reinforces the importance of considering troponin elevation as a crucial factor in risk stratification and treatment decisions for patients with acute stroke.

(A,B) TSA plot for the prediction of mortality in (A) Ischemic stroke and (B) Hemorrhagic stroke with respect to elevated cTn Levels.

 Discussion

Our findings highlights the significance of routinely assessing admission cTn in stroke patients, emphasizing its association with higher mortality rates. Existing literature has consistently reported the association between elevated troponin levels and all-cause mortality across various stroke types (10, 12). Studies have shown that baseline troponin levels predict poor outcomes in both in-hospital and last follow-up scenarios, irrespective of acute coronary syndrome (69, 71, 72). Furthermore, higher blood troponin levels during the acute phase of acute spontaneous ICH are linked with unfavorable outcomes (69, 71, 72). Similar findings are observed in patients with spontaneous subarachnoid hemorrhage, where an increased risk of cerebral ischemia and death is demonstrated (13, 14, 60).

The current meta-analysis supports and reinforces these findings, indicating that elevated troponin levels serve as predictors for both in-hospital and follow-up mortalities for AIS with additional finding of other subtypes of stroke including SAH and ICH. Elevated cTn levels were significantly showed a higher predictive risk for In-hospital mortality and last follow-up mortality in both AIS as well as SAH. However, no significant predictive risk between elevated cTn levels and in-hospital mortality for ICH patients. However, it’s crucial to note that this observation may be influenced by the limited inclusion of only seven studies in the overall analysis.

Previous findings have reported that elevation of cardiac troponin has been reported to occur in ICH patients along with only 1.2% of them died of cardiac causes (69). Although previous studies have been tried to address hypothesis that elevated cardiac troponin might serve as prognostic markers for prediction of adverse clinical events, the results were largely inconsistent and inconclusive with regard to ICH. The previous study demonstrated that elevated troponin levels were associated with higher mortality following ICH (69). Subsequently, the utility of elevated troponin levels for prediction of mortality was confirmed in surgical ICH patients (74), but was not found to be consistently associated with in-hospital mortality in Chinese ICH patients (71). Small sample sizes (less than 240 stroke patients) and ethnic variability probably contribute to the negative results and discrepancies. Similarly in our meta-analysis, only seven ICH studies were included and we observed non-significant association with the elevated level of Troponin.

Approximately 18%–20% (75–77) of ischemic stroke patients present with elevated high-sensitive Troponin T (hsTnT) levels on admission, which can be attributed to various factors including renal failure, chronic heart failure, myocardial infarction (MI), and stress-related cardiomyopathies such as neurogenic stunned myocardium (NSM). NSM, characterized by contraction band necrosis at the cellular level, manifests with elevated hsTnT levels and electrocardiographic abnormalities (78–81). While some patients can be differentiated using ECG and echocardiography, overlap in diagnostic criteria complicates diagnosis for others. Despite common assumptions in stroke centers, attributing elevated hsTnT levels solely to brain or heart origin may not always hold true, as MI patients have an increased risk of stroke (82), even with marginally elevated hsTnT levels, raising questions about predictive value in differentiating NSM from MI (83).

As per the 2023 Guideline for the Management of Patients with SAH by AHA/ASA (84), certain medical parameters, such as BMI, hypertension, hyperglycemia, troponin levels, hyperthermia, peak white blood cell count, C-reactive protein, and high neutrophil counts, have been linked to clinical outcomes in SAH. However, it is emphasized that additional investigation is necessary to determine their prognostic value and influence on treatment outcomes. Furthermore, the guideline underscores the active exploration of novel biomarkers, encompassing imaging, serum, and cerebrospinal fluid (CSF), in the field of SAH. Ongoing research incorporating advanced proteomic, genomic, and other biological marker methods, in conjunction with existing clinical, radiographic, and physiological monitoring data, is deemed essential. These efforts aim to shed light on the potential use of biomarkers for prognosis and interventions, ultimately contributing to improved outcomes in patients with SAH.

The COVID-19 pandemic has placed unprecedented strain on stroke services globally, disrupting healthcare delivery and raising concerns about its impact on stroke outcomes (85). Despite these challenges, our meta-analysis did not identify any explicit instances linking the pandemic with influential impacts on stroke management or patient outcomes across included studies. This highlights the need for further research to understand the nuanced interplay between COVID-19 and stroke care delivery, while also emphasizing the importance of developing adaptive strategies and fostering interdisciplinary collaborations to mitigate the pandemic’s adverse effects on stroke services and ensure optimal patient care.

Clinical decision-making regarding troponin elevations in stroke patients is a multifaceted challenge that requires careful consideration of various factors. While elevated troponin levels in stroke patients can indicate myocardial injury, termed “troponitis,” it’s essential to recognize that other contributing factors such as stress, sepsis, or renal dysfunction may also lead to troponin elevation, particularly in the acute phase of a stroke (86). Therefore, clinicians must conduct a thorough evaluation to differentiate between myocardial infarction and other causes of troponin elevation (87). This evaluation typically involves a comprehensive clinical assessment, including medical history, physical examination, electrocardiography, and imaging studies such as echocardiography or cardiac MRI (88).

Additionally, clinicians may utilize risk stratification tools or algorithms specific to stroke patients with troponin elevations to guide further diagnostic and therapeutic interventions. Collaboration between neurologists, cardiologists, and other specialists is crucial in developing a cohesive management plan tailored to the individual patient’s needs, balancing the risks and benefits of interventions such as antiplatelet therapy, anticoagulation, or coronary angiography (89). Ultimately, the decision-making process should prioritize patient safety, optimizing outcomes, and improving overall care in stroke units. Ongoing research and consensus guidelines from professional societies play a vital role in informing evidence-based practices and advancing our understanding of troponin elevations in stroke patients.

Study limitations

While the study has strengths, it acknowledges limitations, including: (1) using a single baseline cTn assessment time point and non-standardized measurement procedures, potentially introducing misclassification; (2) lacking information on important confounders like infarction locations, stroke severity, time from symptom onset, and type of recanalization therapies, which could bias the relationship between elevated cTn and mortality; (3) absence of data on functional outcomes like the modified Rankin Scale; and (4) variations in cut-off values, assay methods, and follow-up periods across individual studies contributed to high heterogeneity from pooled analysis by troponin assays, complicating result interpretation.

 Conclusion

Elevated troponin levels can serve as a promising predictive marker for both in-hospital and last follow-up mortality in AIS and SAH patients but not in ICH patients. Further prospective studies are needed to validate our findings along with exploring the preventive management of mortality in acute stroke settings.

 Data availability statement

The original contributions presented in the study are included in the article/Supplementary material, further inquiries can be directed to the corresponding author.

 Author contributions

AG: Writing – review & editing, Writing – original draft, Methodology, Data curation. MS: Investigation, Writing – review & editing, Methodology, Data curation, Project administration. PK: Writing – review & editing, Writing – original draft, Supervision, Software, Formal analysis, Conceptualization.

 Funding

The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.

 Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

 Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

 Supplementary material

The Supplementary material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fneur.2024.1351925/full#supplementary-material

1 http://www.endmemo.com

2 https://www.unitconverters.net/

References Tadi P Lui F. Acute Stroke In: StatPearls. Treasure Island (FL): StatPearls Publishing (2023) Roman-Filip C Catană M-G Mihăilă R-G. Prognostic markers for ischemic stroke—are they truly reliable? Med Pharm Rep. (2023) 96:65–70. doi: 10.15386/mpr-2365, PMID: 36818315 Saceleanu VM Toader C Ples H Covache-Busuioc RA Costin HP Bratu BG . Integrative approaches in acute ischemic stroke: from symptom recognition to future innovations. Biomedicines. (2023) 11:2617. doi: 10.3390/biomedicines11102617, PMID: 37892991 Wettersten N Maisel A. Role of cardiac troponin levels in acute heart failure. Card Fail Rev. (2015) 1:102–6. doi: 10.15420/cfr.2015.1.2.102, PMID: 28785441 Grefkes C Fink GR. Recovery from stroke: current concepts and future perspectives. Neurol Res Pract. (2020) 2:17. doi: 10.1186/s42466-020-00060-6, PMID: 33324923 Fan Y Jiang M Gong D Man C Chen Y. Cardiac troponin for predicting all-cause mortality in patients with acute ischemic stroke: a meta-analysis. Biosci Rep. (2018) 38:BSR20171178. doi: 10.1042/BSR20171178 Bohr A Memarzadeh K. The rise of artificial intelligence in healthcare applications. Artif Intell Healthc. (2020) 25–60:2. doi: 10.1016/B978-0-12-818438-7.00002-2 Abdi S Oveis-Gharan S Sinaei F Ghorbani A. Elevated troponin T after acute ischemic stroke: association with severity and location of infarction. Iran J Neurol. (2015) 14:35–40. PMID: 25874055 Etgen T Baum H Sander K Sander D. Cardiac troponins and N-terminal pro-brain natriuretic peptide in acute ischemic stroke do not relate to clinical prognosis. Stroke. (2005) 36:270–5. doi: 10.1161/01.STR.0000151364.19066.a1, PMID: 15604421 Alhazzani A Kumar A Algahtany M Rawat D. Role of troponin as a biomarker for predicting outcome after ischemic stroke. Brain Circ. (2021) 7:77–84. doi: 10.4103/bc.bc_51_20, PMID: 34189350 Broersen LHA Stengl H Nolte CH Westermann D Endres M Siegerink B . Association between high-sensitivity cardiac troponin and risk of stroke in 96 702 individuals: a Meta-analysis. Stroke. (2020) 51:1085–93. doi: 10.1161/STROKEAHA.119.028323, PMID: 32078461 Dous GV Grigos AC Grodman R. Elevated troponin in patients with acute stroke – is it a true heart attack? Egypt Heart J. (2017) 69:165–70. doi: 10.1016/j.ehj.2017.01.005, PMID: 29622972 Memar Montazerin S Chi G Marandi R Najafi H Shojaei F Lee JJ . Evaluation of cardiac troponin and adverse outcomes after aneurysmal subarachnoid hemorrhage: a systematic review and Meta-analysis. Neurocrit Care. (2022) 36:650–61. doi: 10.1007/s12028-021-01368-0, PMID: 34686997 Zhang L Wang Z Qi S. Cardiac troponin elevation and outcome after subarachnoid hemorrhage: a systematic review and Meta-analysis. J Stroke Cerebrovasc Dis. (2015) 24:2375–84. doi: 10.1016/j.jstrokecerebrovasdis.2015.06.030 Zhang Y Ouyang M Qiu J Cao X Xu B Sui Y. Prognostic value of serum cardiac troponin in acute ischemic stroke: an updated systematic review and Meta-analysis. J Stroke Cerebrovasc Dis. (2022) 31:106444. doi: 10.1016/j.jstrokecerebrovasdis.2022.106444, PMID: 35339855 Lippi G Cervellin G Sanchis-Gomar F. Predicting mortality with cardiac troponins: recent insights from meta-analyses. Diagnosi. (2021) 8:37–49. doi: 10.1515/dx-2019-0061, PMID: 31622246 Pitliya A AlEdani EM Bhangu JK Javed K Manshahia PK Nahar S . The impact of elevated troponin levels on clinical outcomes in patients with acute ischemic stroke: a systematic review. Ann Indian Acad Neurol. (2023) 26:641–54. doi: 10.4103/aian.aian_567_23, PMID: 38022445 Cumpston M Li T Page MJ Chandler J Welch VA Higgins JP . Updated guidance for trusted systematic reviews: a new edition of the Cochrane handbook for systematic reviews of interventions. Cochrane Database Syst Rev. (2019) 10:ED000142. doi: 10.1002/14651858.ED000142 Moher D Shamseer L Clarke M Ghersi D Liberati A Petticrew M . Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. (2015) 4:1. doi: 10.1186/2046-4053-4-1 Stang A . Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. (2010) 25:603–5. doi: 10.1007/s10654-010-9491-z, PMID: 20652370 Begg CB Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. (1994) 50:1088–101. doi: 10.2307/2533446 Egger M Smith GD Schneider M Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. (1997) 315:629–34. doi: 10.1136/bmj.315.7109.629, PMID: 9310563 James P . Relation between troponin T concentration and mortality in patients presenting with an acute stroke: observational study. BMJ. (2000) 320:1502–4. doi: 10.1136/bmj.320.7248.1502, PMID: 10834890 Troøyen M Indredavik B. Myocardial damage in acute stroke assessed with troponin I. Tidsskr Nor Laegeforen. (2001) 121:421–5. Di Angelantonio E . Prognostic significance of admission levels of troponin I in patients with acute ischaemic stroke. J Neurol Neurosurg Psychiatry. (2005) 76:76–81. doi: 10.1136/jnnp.2004.041491, PMID: 15607999 Barber M Morton JJ Macfarlane PW Barlow N Roditi G Stott DJ. Elevated troponin levels are associated with Sympathoadrenal activation in acute Ischaemic stroke. Cerebrovasc Dis. (2007) 23:260–6. doi: 10.1159/000098325, PMID: 17199083 Jensen JK Kristensen SR Bak S Atar D Høilund-Carlsen PF Mickley H. Frequency and significance of troponin T elevation in acute ischemic stroke. Am J Cardiol. (2007) 99:108–12. doi: 10.1016/j.amjcard.2006.07.071, PMID: 17196472 Sandhu R Aronow WS Rajdev A Sukhija R Amin H D'aquila K . Relation of cardiac troponin I levels with in-hospital mortality in patients with ischemic stroke, intracerebral hemorrhage, and subarachnoid hemorrhage. Am J Cardiol. (2008) 102:632–4. doi: 10.1016/j.amjcard.2008.04.036, PMID: 18721527 Hajdinjak E Klemen P Grmec Š. Prognostic value of a single prehospital measurement of N-terminal pro-brain natriuretic peptide and troponin T after acute Ischaemic stroke. J Int Med Res. (2012) 40:768–76. doi: 10.1177/147323001204000243, PMID: 22613442 Scheitz JF Endres M Mochmann H-C Audebert HJ Nolte CH. Frequency, determinants and outcome of elevated troponin in acute ischemic stroke patients. Int J Cardiol. (2012) 157:239–42. doi: 10.1016/j.ijcard.2012.01.055 Jensen JK Ueland T Aukrust P Antonsen L Kristensen SR Januzzi JL . Highly sensitive troponin T in patients with acute ischemic stroke. Eur Neurol. (2012) 68:287–93. doi: 10.1159/000341340, PMID: 23051820 Beaulieu-Boire I Leblanc N Berger L Boulanger J-M. Troponin elevation predicts atrial fibrillation in patients with stroke or transient ischemic attack. J Stroke Cerebrovasc Dis. (2013) 22:978–83. doi: 10.1016/j.jstrokecerebrovasdis.2012.01.008 Stahrenberg R Niehaus CF Edelmann F Mende M Wohlfahrt J Wasser K . High-sensitivity troponin assay improves prediction of cardiovascular risk in patients with cerebral ischaemia. J Neurol Neurosurg Psychiatry. (2013) 84:479–87. doi: 10.1136/jnnp-2012-303360, PMID: 23355808 Scheitz JF Mochmann HC Erdur H Tütüncü S Haeusler KG Grittner U . Prognostic relevance of cardiac troponin T levels and their dynamic changes measured with a high-sensitivity assay in acute ischaemic stroke: analyses from the TRELAS cohort. Int J Cardiol. (2014) 177:886–93. doi: 10.1016/j.ijcard.2014.10.036, PMID: 25453407 Lasek-Bal A Kowalewska-Twardela T Gąsior Z Warsz-Wianecka A Haberka M Puz P . The significance of troponin elevation for the clinical course and outcome of first-ever Ischaemic stroke. Cerebrovasc Dis. (2014) 38:212–8. doi: 10.1159/000365839, PMID: 25358959 Faiz KW Thommessen B Einvik G Brekke PH Omland T Rønning OM. Determinants of high sensitivity cardiac troponin T elevation in acute ischemic stroke. BMC Neurol. (2014) 14:96. doi: 10.1186/1471-2377-14-96, PMID: 24885286 Raza F Alkhouli M Sandhu P Bhatt R Bove AA. Elevated cardiac troponin in acute stroke without acute coronary syndrome predicts long-term adverse cardiovascular outcomes. Stroke Res Treat. (2014) 2014:1–6. doi: 10.1155/2014/621650, PMID: 25530906 Batal O Jentzer J Balaney B Kolia N Hickey G Dardari Z . The prognostic significance of troponin I elevation in acute ischemic stroke. J Crit Care. (2016) 31:41–7. doi: 10.1016/j.jcrc.2015.09.018, PMID: 26547807 Maoz A Rosenberg S Leker RR. Increased high-sensitivity troponin-T levels are associated with mortality after ischemic stroke. J Mol Neurosci. (2015) 57:160–5. doi: 10.1007/s12031-015-0593-7 Su Y-C Huang K-F Yang F-Y Lin S-K. Elevation of troponin I in acute ischemic stroke. PeerJ. (2016) 4:e1866. doi: 10.7717/peerj.1866, PMID: 27076999 Budincevic H Sremec J Crnac P Ostojic V Galic E Bielen I. Impact of troponin I on outcome of ischemic stroke patients. Rom J Intern Med. (2017) 55:19–22. doi: 10.1515/rjim-2016-0044 Peddada K Cruz-Flores S Goldstein LB Feen E Kennedy KF Heuring T . Ischemic stroke with troponin elevation: patient characteristics, resource utilization, and in-hospital outcomes. Cerebrovasc Dis. (2016) 42:213–23. doi: 10.1159/000445526, PMID: 27160243 Akpinar O . Prognostic value of troponin t in patients with acute ischemic stroke in EMERGENCY department. Acta Medica Mediterr. (2017) 757–761:111. doi: 10.19193/0393-6384_2017_5_111 Wrigley P Khoury J Eckerle B Alwell K Moomaw CJ Woo D . Prevalence of positive troponin and echocardiogram findings and association with mortality in acute ischemic stroke. Stroke. (2017) 48:1226–32. doi: 10.1161/STROKEAHA.116.014561 Ahn S-H Lee JS Kim YH Kim BJ Kim YJ Kang DW . Prognostic significance of troponin elevation for long-term mortality after ischemic stroke. J Stroke. (2017) 19:312–22. doi: 10.5853/jos.2016.01942, PMID: 28877565 Fathy HA Ashour WMR Elserafy TS Amer MM. The prognostic value of elevated cardiac troponin-I in short-term outcome of acute ischemic stroke. Int J Clin Exp Neurol. (2018) 6:1–7. He L Wang J Dong W. The clinical prognostic significance of hs-cTnT elevation in patients with acute ischemic stroke. BMC Neurol. (2018) 18:118. doi: 10.1186/s12883-018-1121-5, PMID: 30124165 Ahn S-H Kim YH Lee JS Han JH Kim SY Kang DW . Troponin I levels and long-term outcomes in acute ischemic stroke patients. J Am Coll Cardiol. (2019) 73:525–6. doi: 10.1016/j.jacc.2018.11.022, PMID: 30704584 He M Panchangam S Cruz B Mukherjee D. Underutilization of cardiac therapies in patients with acute ischemic stroke and elevated troponin. Cardiovasc Hematol Agents Med Chem. (2019) 17:144–51. doi: 10.2174/1871525717666191019115338, PMID: 31629400 Terceño M Silva Y Bashir S Vera-Monge V Buxó M Serena J. Troponin T predicts Cardioembolic Aetiology and clinical outcome in undetermined Ischaemic stroke in Hyperacute phase. J Stroke Cerebrovasc Dis. (2020) 29:104528. doi: 10.1016/j.jstrokecerebrovasdis.2019.104528, PMID: 31806451 Sui Y Liu T Luo J Xu B Zheng L Zhao W . Elevation of high-sensitivity cardiac troponin T at admission is associated with increased 3-month mortality in acute ischemic stroke patients treated with thrombolysis. Clin Cardiol. (2019) 42:881–8. doi: 10.1002/clc.23237, PMID: 31334875 Cao Y-Z Zhao LB Liu S Liu QH Jiang L Zhou CG . Prognostic value of elevated high-sensitivity cardiac troponin T levels in patients with acute ischemic stroke treated with endovascular thrombectomy. J Clin Neurosci. (2019) 64:145–9. doi: 10.1016/j.jocn.2019.03.030, PMID: 30929959 Alkhachroum AM Miller B Chami T Tatsuoka C Sila C. A troponin study on patients with ischemic stroke, intracerebral hemorrhage and subarachnoid hemorrhage: type II myocardial infarction is significantly associated with stroke severity, discharge disposition and mortality. J Clin Neurosci. (2019) 64:83–8. doi: 10.1016/j.jocn.2019.04.005, PMID: 31014907 Thapa P Agrawal JP Baniya R. A study on elevation of troponin I in ischemic stroke as an independent prognostic marker of outcomes. Nepal J Neurosci. (2020) 17:26–34. doi: 10.3126/njn.v17i2.30224 Scheitz JF Stengl H Nolte CH Landmesser U Endres M. Neurological update: use of cardiac troponin in patients with stroke. J Neurol. (2021) 268:2284–92. doi: 10.1007/s00415-020-10349-w, PMID: 33372247 Nageeb RS Omran AA Mohamed WS. Troponin-I elevation predicts outcome after thrombolysis in ischemic stroke patients. Egypt J Neurol Psychiatry Neurosurg. (2021) 57:4. doi: 10.1186/s41983-020-00256-2 Miraj AA Mohammad QD Rahman S Miah S. Elevation of troponin I in ischemic stroke of outcomes in patients with acute stroke. Acute Stroke Br J Res. (2022) 9:120. doi: 10.21767/2394-3718.9.12.120 Chen F Bai X Wang X Zhang L Wang F Huang L . Impact of high-sensitivity troponin elevation and dynamic changes on 90-day mortality in patients with acute ischemic stroke after mechanical thrombectomy: results from an observational cohort. J NeuroInterventional Surg. (2022) 15:1142–7. doi: 10.1136/jnis-2022-019682, PMID: 36597941 Kim BS Park JJ Chang H Kim SH Kwon CH Chung SM . Association of High-Sensitivity Troponin I with cardiac and cerebrovascular events in patient after ischemic stroke. Cerebrovasc Dis. (2023) 52:153–9. doi: 10.1159/000525920, PMID: 35908539 Deibert E Barzilai B Braverman AC Edwards DF Aiyagari V Dacey R . Clinical significance of elevated troponin I levels in patients with nontraumatic subarachnoid hemorrhage. J Neurosurg. (2003) 98:741–6. doi: 10.3171/jns.2003.98.4.0741, PMID: 12691398 Naidech AM Kreiter KT Janjua N Ostapkovich ND Parra A Commichau C . Cardiac troponin elevation, cardiovascular morbidity, and outcome after subarachnoid hemorrhage. Circulation. (2005) 112:2851–6. doi: 10.1161/CIRCULATIONAHA.105.533620, PMID: 16267258 Ramappa P Thatai D Coplin W Gellman S Carhuapoma JR Quah R . Cardiac troponin-I: a predictor of prognosis in subarachnoid hemorrhage. Neurocrit Care. (2008) 8:398–403. doi: 10.1007/s12028-007-9038-7, PMID: 18087680 Gupte M John S Prabhakaran S Lee VH. Troponin elevation in subarachnoid hemorrhage does not impact in-hospital mortality. Neurocrit Care. (2013) 18:368–73. doi: 10.1007/s12028-012-9813-y Duello KM Nagel JP Thomas CS Blackshear JL Freeman WD. Relationship of troponin T and age- and sex-adjusted BNP elevation following subarachnoid hemorrhage with 30-day mortality. Neurocrit Care. (2015) 23:59–65. doi: 10.1007/s12028-014-0105-6, PMID: 25586941 Guette P Launey Y Arnouat M Bleichner JP Masseret E Rousseau C . Prognostic value of high-sensitivity troponin T in aneurysmal subarachnoid hemorrhage: a prospective observational study. Brain Inj. (2019) 33:1372–8. doi: 10.1080/02699052.2019.1641742, PMID: 31296071 Akkermans A Peelen LM Van Waes JA Rinkel GJ Van Klei WA. Cardiac events within one year after a subarachnoid haemorrhage: the predictive value of troponin elevation after aneurysm occlusion. Eur J Prev Cardiol. (2019) 26:420–8. doi: 10.1177/2047487318776098 Lin F Chen Y He Q Zeng C Zhang C Chen X . Prognostic value of elevated cardiac troponin I after aneurysmal subarachnoid hemorrhage. Front Neurol. (2021) 12:677961. doi: 10.3389/fneur.2021.677961, PMID: 34135855 Anetsberger A Jungwirth B Blobner M Ringel F Bernlochner I Heim M . Association of Troponin T levels and functional outcome 3 months after subarachnoid hemorrhage. Sci Rep. (2021) 11:16154. doi: 10.1038/s41598-021-95717-w, PMID: 34373566 Hays A Diringer MN. Elevated troponin levels are CME associated with higher mortality following intracerebral hemorrhage. Neurology. (2006) 66:1330–4. doi: 10.1212/01.wnl.0000210523.22944.9b Chung P-W Won YS Kwon YJ Choi CS Kim BM. Initial troponin level as a predictor of prognosis in patients with intracerebral hemorrhage. J Korean Neurosurg Soc. (2009) 45:355–9. doi: 10.3340/jkns.2009.45.6.355, PMID: 19609419 Xu M Lin J Wang D Liu M Hao Z Lei C. Cardiac troponin and cerebral herniation in acute intracerebral hemorrhage. Brain Behav. (2017) 7:e00697. doi: 10.1002/brb3.697 Gerner ST Auerbeck K Sprügel MI Sembill JA Madžar D Gölitz P . Peak troponin I levels are associated with functional outcome in intracerebral hemorrhage. Cerebrovasc Dis. (2018) 46:72–81. doi: 10.1159/000492395 He Y Liu Q Wang J Wang DW Ding H Wang W. Prognostic value of elevated cardiac troponin I in patients with intracerebral hemorrhage. Clin Cardiol. (2020) 43:338–45. doi: 10.1002/clc.23320, PMID: 31851767 Garrett MC Komotar RJ Starke RM Doshi D Otten ML Connolly ES. Elevated troponin levels are predictive of mortality in surgical intracerebral hemorrhage patients. Neurocrit Care. (2010) 12:199–203. doi: 10.1007/s12028-009-9245-5 Anders B Alonso A Artemis D Schäfer A Ebert A Kablau M . What does elevated high-sensitive troponin I in stroke patients mean: concomitant acute myocardial infarction or a marker for high-risk patients? Cerebrovasc Dis. (2013) 36:211–7. doi: 10.1159/000353875 Darki A Schneck MJ Agrawal A Rupani A Barron JT. Correlation of elevated troponin and echocardiography in acute ischemic stroke. J Stroke Cerebrovasc Dis. (2013) 22:959–61. doi: 10.1016/j.jstrokecerebrovasdis.2011.12.004, PMID: 22244712 Kerr G Ray G Wu O Stott DJ Langhorne P. Elevated troponin after stroke: a systematic review. Cerebrovasc Dis. (2009) 28:220–6. doi: 10.1159/000226773, PMID: 19571535 Nguyen H Zaroff JG. Neurogenic stunned myocardium. Curr Neurol Neurosci Rep. (2009) 9:486–91. doi: 10.1007/s11910-009-0071-0 Dombrowski K Laskowitz D. Cardiovascular manifestations of neurologic disease. Handb Clin Neurol. (2014) 119:3–17. doi: 10.1016/B978-0-7020-4086-3.00001-1 Apak I Iltumur K Tamam Y Kaya N. Serum cardiac troponin T levels as an indicator of myocardial injury in ischemic and hemorrhagic stroke patients. Tohoku J Exp Med. (2005) 205:93–101. doi: 10.1620/tjem.205.93, PMID: 15673967 Mazzeo AT Micalizzi A Mascia L Scicolone A Siracusano L. Brain-heart crosstalk: the many faces of stress-related cardiomyopathy syndromes in anaesthesia and intensive care. Br J Anaesth. (2014) 112:803–15. doi: 10.1093/bja/aeu046, PMID: 24638232 Visser CA Kan G Lie KI Durrer D. Left ventricular thrombus following acute myocardial infarction: a prospective serial echocardiographic study of 96 patients. Eur Heart J. (1983) 4:333–7. doi: 10.1093/oxfordjournals.eurheartj.a061470 Heldner MR Pilgrim T Wustmann K Hsieh K Mattle HP Arnold M . Acute carotid T occlusion in a young patient: cryptogenic origin? Stroke. (2014) 45:e125–7. doi: 10.1161/STROKEAHA.114.005388 Hoh BL Ko NU Amin-Hanjani S Chou SH-Y Cruz-Flores S Dangayach NS . 2023 guideline for the Management of Patients with Aneurysmal Subarachnoid Hemorrhage: a guideline from the American Heart Association/American Stroke Association. Stroke. (2023) 54:e314–70. doi: 10.1161/STR.0000000000000436 Small C Mehkri Y Panther E Felisma P Lucke-Wold B. Coronavirus Disease-2019 and stroke: pathophysiology and management. Can J Neurol Sci J Can Sci Neurol. (2023) 50:495–502. doi: 10.1017/cjn.2022.267 van Beek DEC van der Horst ICC Scheeren TWL. Troponin elevations after cardiac surgery: just “Troponitis”? In: Vincent J-L , editor. Annual update in intensive care and Emergency medicine 2020. Cham: Springer International Publishing (2020). 113–24. Body R Carlton E. Understanding cardiac troponin part 1: avoiding troponinitis. Emerg Med J EMJ. (2018) 35:120–5. doi: 10.1136/emermed-2017-206812, PMID: 28784609 Korff S Katus HA Giannitsis E. Differential diagnosis of elevated troponins. Heart. (2006) 92:987–93. doi: 10.1136/hrt.2005.071282, PMID: 16775113 Alaour B Liew F Kaier TE. Cardiac troponin—diagnostic problems and impact on cardiovascular disease. Ann Med. (2018) 50:655–65. doi: 10.1080/07853890.2018.1530450, PMID: 30265127